Ivermectine Liconsa (Ivermectin)

Ivermectin binds to glutamate‑gated chloride channels that exist on the nerve and muscle cells of invertebrates. This binding forces an influx of chloride ions, hyperpolarising the cells, which leads to paralysis and death of the parasite. Human cells lack these specific channels, providing a high degree of selectivity.

The exact dose of Ivermectine Liconsa is set by the prescribing clinician based on factors such as the patient’s weight, the specific infection being treated, severity of disease and any relevant comorbidities. No universal dosing schedule is provided here; the prescriber will calculate the appropriate regimen.

Safety data for ivermectin in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit to the mother clearly outweighs any possible risk to the fetus or infant. Healthcare providers should discuss individual risk factors before initiating therapy.

To request Ivermectine Liconsa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Ivermectin belongs to the macrocyclic lactone class and offers a broad spectrum of activity against both nematodes and ectoparasites. Compared with drugs such as albendazole or mebendazole, ivermectin often requires a single oral dose for many indications, but its efficacy may be reduced when used with strong CYP3A4 inducers. Choice of therapy depends on the specific parasite, resistance patterns and patient factors.

Ivermectine Liconsa should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight and excessive heat to maintain potency throughout its shelf life.

The medication is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. The exact administration instructions, including whether to take it on an empty stomach, will be provided on the prescription label.

Serious adverse events, although rare, can include severe skin reactions such as Stevens‑Johnson syndrome, significant hepatic injury, and neurologic toxicity manifesting as seizures or altered consciousness. Patients should seek immediate medical attention if they experience any of these symptoms.

Ivermectine Liconsa is contraindicated in individuals with a known hypersensitivity to ivermectin or any of the product’s excipients. Caution is also advised for patients with severe hepatic impairment, certain neurological disorders, or those taking other neurotoxic medications, as the risk of adverse effects may be higher.